Stock Track | ImmunityBio Soars 5.26% as Earnings Beat Expectations Despite Revenue Miss

Stock Track

Mar 05, 2025

ImmunityBio, Inc. (NASDAQ: IBRX) saw its stock price soar 5.26% in Tuesday's intraday trading session following the release of its full-year 2024 financial results.

While the biotechnology company reported a net loss of $413.6 million for the year, this figure represented a 29% narrowing of losses compared to the previous year. Additionally, ImmunityBio's earnings per share (EPS) surpassed analyst expectations, despite revenue falling short of estimates.

Looking ahead, the company forecasts an impressive 55% annual revenue growth on average over the next three years, outpacing the 20% growth forecast for the broader American biotechs industry. However, investors are advised to consider the four warning signs identified by analysts, including three significant ones, which may impact the company's future performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1190881856"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1190881856\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1190881856?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-05 01:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190881856","market":"us","top_or_hot":-1,"title":"Stock Track | ImmunityBio Soars 5.26% as Earnings Beat Expectations Despite Revenue Miss","media":"Stock Track","content":"<p>ImmunityBio, Inc. (NASDAQ: IBRX) saw its stock price soar 5.26% in Tuesday's intraday trading session following the release of its full-year 2024 financial results.</p>\n\n<p>While the biotechnology company reported a net loss of $413.6 million for the year, this figure represented a 29% narrowing of losses compared to the previous year. Additionally, ImmunityBio's earnings per share (EPS) surpassed analyst expectations, despite revenue falling short of estimates.</p>\n\n<p>Looking ahead, the company forecasts an impressive 55% annual revenue growth on average over the next three years, outpacing the 20% growth forecast for the broader American biotechs industry. However, investors are advised to consider the four warning signs identified by analysts, including three significant ones, which may impact the company's future performance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ImmunityBio Soars 5.26% as Earnings Beat Expectations Despite Revenue Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ImmunityBio Soars 5.26% as Earnings Beat Expectations Despite Revenue Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-05 01:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ImmunityBio, Inc. (NASDAQ: IBRX) saw its stock price soar 5.26% in Tuesday's intraday trading session following the release of its full-year 2024 financial results.</p>\n\n<p>While the biotechnology company reported a net loss of $413.6 million for the year, this figure represented a 29% narrowing of losses compared to the previous year. Additionally, ImmunityBio's earnings per share (EPS) surpassed analyst expectations, despite revenue falling short of estimates.</p>\n\n<p>Looking ahead, the company forecasts an impressive 55% annual revenue growth on average over the next three years, outpacing the 20% growth forecast for the broader American biotechs industry. However, investors are advised to consider the four warning signs identified by analysts, including three significant ones, which may impact the company's future performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1190881856","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190881856","pubTimestamp":1741107756,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ImmunityBio, Inc.  saw its stock price soar 5.26% in Tuesday's intraday trading session following the release of its full-year 2024 financial results.While the biotechnology company reported a net loss of $413.6 million for the year, this figure represented a 29% narrowing of losses compared to the previous year. Additionally, ImmunityBio's earnings per share  surpassed analyst expectations, despite revenue falling short of estimates.Looking ahead, the company forecasts an impressive 55% annual ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"股票追踪ImmunityBio飙升5.26%，尽管营收未达预期，但盈利仍超出预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"ImmunityBio, Inc. (NASDAQ: IBRX) saw its stock price soar 5.26% in Tuesday's intraday trading session following the release of its full-year 2024 financial results.\nWhile the biotechnology company reported a net loss of $413.6 million for the year, this figure represented a 29% narrowing of losses compared to the previous year. Additionally, ImmunityBio's earnings per share (EPS) surpassed analyst expectations, despite revenue falling short of estimates.\nLooking ahead, the company forecasts an impressive 55% annual revenue growth on average over the next three years, outpacing the 20% growth forecast for the broader American biotechs industry. However, investors are advised to consider the four warning signs identified by analysts, including three significant ones, which may impact the company's future performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}